Points principaux de la réunion du comité d’évaluation des risques en matière de pharmacovigilance (PRAC) 7 – 10 février 2022
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-february-2022
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-february-2022
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure_en.pdf
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure_en.pdf
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022
https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk#full-publication-update-history
https://www.swissmedic.ch/swissmedic/fr/home/medicaments-a-usage-humain/authorisations/informations/anpassung-wl-befristete-zulassung-ham.html
Points principaux de la réunion du PRAC 10 – 13 janvier 2022
Indicateurs utilisés dans les inspections de pharmacovigilance entre avril 2020 et mars 2021 – MHRA
https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_en.pdf
https://www.ema.europa.eu/en/documents/other/guidance-electronic-submission-information-investigational-medicinal-products-human-use-extended_en.pdf